OncoVax

Vaccinogen is a clinical-stage biotechnology company focused on developing autologous tumor cell vaccines for the treatment of various cancers. The company's lead product candidate, OncoVax, is a personalized immunotherapy designed to prevent the recurrence of colon cancer by using a patient's own tumor cells to stimulate a specific immune response. OncoVax has demonstrated significant efficacy in Phase 3 clinical trials for Stage II colon cancer, showing a reduction in the risk of recurrence and death. Vaccinogen aims to leverage its proprietary manufacturing processes to provide cost-effective, individualized cancer treatments that improve long-term patient outcomes.